We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Lemborexant

News List

Eisai acquires rights to lemborexant from Purdue Pharma pharmaceutical-technology
May 05, 2019
Eisai has bought the rights to investigational drug lemborexant from Purdue Pharma, ending a global development and commercialisation alliance signed in 2015.
FDA accepts NDA for Lemborexant to treat Insomnia biospectrumasia
March 12, 2019
The NDA submission was based on data from the clinical development program including two pivotal Phase 3 studies of lemborexant - SUNRISE 1 (Study 304) and SUNRISE 2 (Study 303).
New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States drugs
January 24, 2019
Eisai Co., Ltd. (CEO: Haruo Naito, “Eisai”) and Purdue Pharma L.P. (President and CEO: Craig Landau, MD, “Purdue Pharma”) today announced that ...
Eisai and Purdue Pharma seek US approval for lemborexant to treat insomnia pharmaceutical-technology
January 17, 2019
Eisai and its partner Purdue Pharma have submitted new drug application to the US Food and Drug Administration (FDA) seeking approval for lemborexant to treat insomnia, a sleep disorder.....
NDA for Lemborexant Submitted in the United States americanpharmaceuticalreview
January 16, 2019
Eisai and Purdue Pharma announced a new drug application has been submitted to the U.S. Food and Drug Administration (FDA) for lemborexant ....